Medimmune Limited

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Humabs Biomed Sa

Boston Pharmaceuticals, Inc.

US Government As Represented by the Secretary of the Army

Xiaodong Xiao

Dimiter Stanchev Dimitrov

Reena Varkey

Ira H Pastan

Davide Corti

Partha S Chowdhury

Charles K Stover

Martina Beltramello

Elisabetta Cameroni

Qun Wang

Gilad Kaplan

Meghan Pennini

Melissa Marie Damschroder

Ronald Herbst

Stacey Drabic

Ping Tsui

Qun Du

Catherine Ettinger

Jodi Karnell

Laura Carter

Brian Michael Naiman

David Tice

Krista Lynne Kinneer

Anna DeMarco

Chew-shun Chang

Jamese Johnson Hilliard

Elaine M Hurt

Chien-Ying Chang

Kei Amemiya

The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to02 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiellapneumoniae) and/or protects mice from a lethalchallenge. The present disclosure also provides methods of reducing(e.g.,) or treating or preventing(e.g.,) infection in a subject comprising administering thepneumoniae 02 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.

Anti-O2 antibodies and uses thereof

The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind toO1 and induce opsonophagocytic killing of(e.g.,). The present disclosure also provides methods of reducing(e.g.,) or treating or preventing(e.g.,) infection in a subject comprising administering theO1 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.

Anti-O1 antibodies and uses thereof

The disclosure is directed to an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The disclosure also provides compositions comprising the antibody-drug conjugate and methods of killing multiple myeloma cells (including multiple myeloma stems cells) that express BCMA by contacting multiple myeloma cells with the ADC.

BCMA monoclonal antibody-drug conjugate

This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.

Antibodies specific for IL-21 and uses thereof

The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind toO2 and induce opsonophagocytic killing of(e.g.,) and/or protects mice from a lethalchallenge. The present disclosure also provides methods of reducing(e.g.,) or treating or preventing(e.g.,) infection in a subject comprising administering theO2 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.

Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (K) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.

Human monoclonal antibodies specific for CD22

This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of DPP-4 levels in samples obtained from human patients. The disclosure further provides novel anti-DPP-4 monoclonal antibodies that recognize human DPP-4, and assay kits comprising one or more of these antibodies.

Assay to detect human DPP-4

In this application are described fully human monoclonal antibodies which specifically recognize F1 or V antigen ofand epitopes recognized by these monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of plague infections in vitro and in vivo.

Human monoclonal antibodies protective against bubonic plague

Growing community of inventors

Frederick, MD, United States of America

Xiaodong Xiao